39 results about "Immunostimulating Complexes" patented technology

The invention relates to TLR ligand formulations that comprise immune stimulating complexes and their use in inducing innate immunity.

Vaccine compositions comprising (a) an oligonucleotide, (b) and immune stimulating complex and (c) an antigen induce a strong interferon-gamma immune response. Both oligonucleotides containing immune stimulatory motifs and oligonucleotides lacking immune stimulatory motifs contribute to an interferon-gamma response when administered with an immune stimulating complex.

The invention discloses a special diluent for swine mycoplasmal pneumonia vaccines. The special diluent mainly contains a recombinant P97R1 protein immunostimulating complex (ISCOM-P97R1); and in addition, the special diluent also possibly contains other water-based adjuvants comprising levomisole, astragalus polysaccharide or/and carbomer. 1 ml of diluent solution contains 0.1-1 mg of QuilA, 0.02-0.2 mg of cholesterol, 0.02-0.2 mg of phosphatidylcholine and 0.4-4 mg of P97R1 antigen; and in addition, 1 ml of diluent solution also possibly contains 2-20 mg of levomisole, 20-100 mg of astragalus polysaccharide or/and 3-10 mg of carbomer and a phosphate buffer solution for the rest. The diluent is specially used for dissolving or diluting the swine mycoplasmal pneumonia vaccines comprising a live vaccine and an inactivated vaccine, has the double effects of complementing vaccine antigen protection spectrums and improving the vaccine cell and humoral immunostimulation capability, can remarkably improve the toxic attack protection efficacy of the vaccines, and also has the advantages of being simple and convenient to operate, good in syringeability and free from remarkable toxic side reaction due to the adoption of a hydrosolvent system at the same time.

The invention relates to the technical field of gene engineering, in particular to an immune enhanced gene vaccine of a hepatitis B virus core antigen (HBcAg). The vaccine is an immune stimulating complex (ISCOM) vaccine consisting of HBcAg and OX40 ligand (OX40L) dual-gene co-expression recombinant eukaryotic vector, saponin Quil A, cholesterol and lecithin. The vaccine can promote immune response of specific T cells of the HBcAg and efficiently induce the anti-virus replication capacity of immune cells, and has good application prospect in the field of hepatitis B virus infection resistance. The invention also relates to a preparation method for the vaccine with simple and convenient operation and low cost.

Production of various Aeromonas hydrophila protective antigen monovalent and multivalent vitelline antibody and its usage in prevention of aquatic animal diseases are disclosed. It utilizes minor-protective antibody to make immune irritant composite egged hen and produce vitelline antibody product. It's safe, efficient, fast, has no harm and residue. It has more output, better immune-system development and functions of nutrients-added, disease-prevention and health-care.

The invention relates to a bath or oral application of immune activate compound in the fish immunity, wherein the invention has the advantages that: said compound ISCOMs is used to bath immunity to improve the antibody level and improve the increment transformation ability of T-lymphocyte, to induce the immune protection; when in the same dosage, the antibody level is higher than non-adjuvant group and the ISM1312 group; and the ISCOMs used in oral can improve the antibody level and improve the increment transformation ability of T-lymphocyte, to induce the immune protection.

The invention discloses a hepatitis B virus dendritic cell therapeutic vaccine and a preparation method thereof. The preparation method thereof includes the steps that: HBcAg-Fc digenic co-expression recombinant eukaryotic vector is constructed; the obtained digenic co-expression recombinant eukaryotic vector is added with saponin Quil A and then is added with cholesterol and lecithin, ice-bath ultrasonic processing is carried out, so that solution is fully mixed and emulsified, PBS dialysis is carried out, and the obtained micro floccus is immunostimulating complex; and the obtained immunostimulating complex activates and simulates dendritic cell, thus obtaining the cell therapeutic vaccine. The vaccine carries out high efficiency transfection on dendritic cell, the generated fusion protein targets the dendritic cell in high efficiency by virtue of Fc segment, thus activating the dendritic cell, promoting immune response of hepatitis B virus core antigen specificity T cell and inducing the antivirus replication capability of immune cell in high efficiency, so that the vaccine can be taken as hepatitis B virus therapeutic vaccine.

A method for the treatment of a condition which is characterized by CD 123-expressing cells in a patient comprises administering to the patient (i) an antibody or antibody fragment which binds selectively to IL-3Rα(CD 123), and (ii) an immunostimulating complex which comprises saponin, a sterol and a phospholipid.

An immunostimulating complex with stable and durable immune effect is prepared from hygrophilic monodas through liquid culturing, centrifugal separating of supernatant, treating it by saturated ammonium sulfate solution, suspending its deposit by PBS dialyzing to obtain toxic, concentrating, adding organic acid, adding Mega-10, treating at 37 deg.C for 4 hr, adding Quil A, cholesterol and lecithin, treating by organic acid, and dialyzing.

The invention relates to a vaccine, in particular to a gene vaccine of sperm-specific cationic channel protein CatSper1. The vaccine is an immune-stimulating complex type vaccine composed of CatSper1-BAFF digenic recombinant eukaryotic vector, saponin Quil A, cholesterol and lecithin; and the vaccine can inhibit the movement of sperms, perform specific reduction of the average farrowing rate and number born of BALB/c mouse and have good application prospect in the immunological contraception field. The invention also relates to a preparation method of the vaccine which has simple operation and low cost.

The invention relates to a preparation technology of vibrio vulnificus whole-bacteria immunity stimulated compound vaccine and the application thereof in aquatic animals. The technology comprises the following steps: (1) pre-amplification and expansion cultivation of the vibrio vulnificus is carried out, (2) blanching is imposed on the vibrio vulnificus in zymogen liquid cultivated, (3) non-viable bacteria inspection is carried out on the bacteria liquid blanched, (4) the inactivated vibrio vulnificus is collected by a centrifuge, (5) an ultrasonic crushing is taken on the inactivated vibrio vulnificus collected, (6) immunity stimulated compound ingredients are prepared, and (7) the immunity stimulated compound is prepared by ultrasonic treatment. The virulence of the vibrio vulnificus selected is quite strong (LD50 is about 200cfu/g), the cultivation condition and optimized culture medium can double the biological content of viable bacteria in the fermentation broth, and the biomass of the vibrio vulnificus cultivated is more than 50mg/ml, thus providing energetic technological support for the industrialized fermentation production of the vibrio vulnificus.